Characteristics at diagnosis of BL
| Variable . | All, n (%); N = 249 . | US, n (%); 140 (56) . | UK, n (%); 109 (44) . | P . |
|---|---|---|---|---|
| Age, y | ||||
| <40 | 92 (37) | 57 (41) | 35 (32) | .19 |
| ≥40 | 157 (63) | 83 (59) | 74 (68) | |
| Sex | ||||
| Male | 210 (84) | 118 (84) | 92 (84) | 1.00 |
| Female | 39 (16) | 22 (16) | 17 (16) | |
| ECOG PS 2-4 | 112 (47) | 41 (32) | 71 (65) | <.001 |
| LDH | ||||
| >ULN | 211 (85) | 116 (83) | 95 (87) | .38 |
| >3× | 123 (49) | 67 (48) | 56 (51) | .61 |
| >5× | 97 (39) | 53 (38) | 44 (40) | .70 |
| Advanced stage | 227 (91) | 128 (92) | 99 (91) | .82 |
| >1 EN sites | 149 (60) | 82 (59) | 67 (61) | .70 |
| CNS involvement | 61 (24) | 42 (30) | 19 (17) | .026 |
| BM involvement | 112 (46) | 60 (44) | 52 (48) | .70 |
| CD4 count, median (IQR) | 217 (90, 392) | 212 (94, 392) | 218 (90, 391) | .91 |
| Undetectable viral load | 52 (21) | 25 (18) | 27 (24) | .63 |
| CD4, >100 cells/µL | 170 (68) | 93 (67) | 77 (70) | .88 |
| CD4, >50 cells/µL | 197 (79) | 109 (78) | 88 (80) | 1.00 |
| cART | 96 (39) | 53 (38) | 43 (39) | .22 |
| Regimen | ||||
| CODOX-M/IVAC | 150 (60) | 45 (32) | 105 (96) | <.001 |
| DA-EPOCH | 63 (25) | 59 (42) | 4 (4) | |
| HyperCVAD/MA | 33 (13) | 33 (24) | 0 | |
| Other | 3 (2) | 3 (2) | 0 | |
| Rituximab-containing regimen | 217 (87) | 131 (94) | 86 (79) | <.001 |
| Variable . | All, n (%); N = 249 . | US, n (%); 140 (56) . | UK, n (%); 109 (44) . | P . |
|---|---|---|---|---|
| Age, y | ||||
| <40 | 92 (37) | 57 (41) | 35 (32) | .19 |
| ≥40 | 157 (63) | 83 (59) | 74 (68) | |
| Sex | ||||
| Male | 210 (84) | 118 (84) | 92 (84) | 1.00 |
| Female | 39 (16) | 22 (16) | 17 (16) | |
| ECOG PS 2-4 | 112 (47) | 41 (32) | 71 (65) | <.001 |
| LDH | ||||
| >ULN | 211 (85) | 116 (83) | 95 (87) | .38 |
| >3× | 123 (49) | 67 (48) | 56 (51) | .61 |
| >5× | 97 (39) | 53 (38) | 44 (40) | .70 |
| Advanced stage | 227 (91) | 128 (92) | 99 (91) | .82 |
| >1 EN sites | 149 (60) | 82 (59) | 67 (61) | .70 |
| CNS involvement | 61 (24) | 42 (30) | 19 (17) | .026 |
| BM involvement | 112 (46) | 60 (44) | 52 (48) | .70 |
| CD4 count, median (IQR) | 217 (90, 392) | 212 (94, 392) | 218 (90, 391) | .91 |
| Undetectable viral load | 52 (21) | 25 (18) | 27 (24) | .63 |
| CD4, >100 cells/µL | 170 (68) | 93 (67) | 77 (70) | .88 |
| CD4, >50 cells/µL | 197 (79) | 109 (78) | 88 (80) | 1.00 |
| cART | 96 (39) | 53 (38) | 43 (39) | .22 |
| Regimen | ||||
| CODOX-M/IVAC | 150 (60) | 45 (32) | 105 (96) | <.001 |
| DA-EPOCH | 63 (25) | 59 (42) | 4 (4) | |
| HyperCVAD/MA | 33 (13) | 33 (24) | 0 | |
| Other | 3 (2) | 3 (2) | 0 | |
| Rituximab-containing regimen | 217 (87) | 131 (94) | 86 (79) | <.001 |
IQR, interquartile range.